Institutional members access full text with Ovid®

Share this article on:

Golden Bullet—Denosumab: Early Rapid Response of Metastatic Giant Cell Tumor of the Bone

Demirsoy, Ugur MD; Karadogan, Meriban MD; Selek, Özgür MD; Anik, Yonca MD; Aksu, Görkem MD; Müezzinoglu, Bahar MD; Corapcioglu, Funda MD

Journal of Pediatric Hematology/Oncology: March 2014 - Volume 36 - Issue 2 - p 156–158
doi: 10.1097/MPH.0000000000000034
Clinical and Laboratory Observations

Giant cell tumor of the bone (GCTB) is usually a benign, locally aggressive tumor with metastatic potential. Histogenesis of GCTB is unknown and a correlation has not been found between histologic and clinical course. For this reason, many authors consider its prognosis unpredictable. Lung metastasis after GCTB treatment is well known and generally has unfavorable outcome, despite varied chemotherapy regimens. Denosumab, which inhibits RANK-RANKL interaction, is a new, promising actor among targeted therapeutic agents for GCTB. In this report, we emphasize on early rapid response to denosumab in metastatic GCTB.

Departments of *Pediatric Oncology

Orthopaedics and Traumatology


§Radiation Oncology

Pathology, Kocaeli University, Umuttepe, 41380 Kocaeli/Turkey

The authors declare no conflict of interest.

Reprints: Funda Corapcioglu, MD, Department of Pediatric Oncology, Kocaeli University, Umuttepe, 41380 Kocaeli/Turkey (e-mail:

Received August 5, 2013

Accepted August 23, 2013

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.